News

According to a poster at the 2025 EADV Congress, barzolvolimab achieved comparable improvements in weekly Urticaria Activity Scores across immunoglobulin E (lgE) subgroups.

Sanofi's brivekimig shows promising phase 2a results for hidradenitis suppurativa (HS), offering hope for effective treatment options at EADV Congress 2025.

At EADV 2025, UCB presented new long-term data demonstrating bimekizumab’s durable efficacy and a consistent safety profile over extended treatment.

STOP-HS1 and STOP-HS2 phase 3 trials showed nearly 60% of patients achieving HiSCR50 by week 24, according to a presentation at EADV 2025.

Join Dermatology Times at the EADV Congress 2025 for expert insights and live updates from Paris, France.

By blocking 2 key inflammation signals, research presented at EADV found bimekizumab may help keep both skin and joints healthier over time.

At EADV, research showed benefits of zasocitinib on quality of life were observed as early as week 4 and sustained through week 12.

Nayan Patel, PharmD, reveals how innovative glutathione delivery transforms skin care, combats oxidative stress, and empowers skin health for lasting results.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.

Biofrontera advances closer to expanding the Ameluz PDT label, as phase 3 follow-up data on actinic keratoses are expected next year.

New guidelines redefine short-term corticosteroid use in patients with AD, urging safer treatment transitions to advanced therapies for better outcomes.

A new hybrid model combining deep learning with clinical data achieved high accuracy in predicting sentinel lymph node metastasis in melanoma.

Experts discuss innovative topical therapies for pediatric AD, emphasizing individualized treatment and the importance of managing itch and sleep quality.

The FDA's groundbreaking decision to waive clinical efficacy studies for a monoclonal antibody biosimilar revolutionizes drug approval, reducing costs and enhancing patient access.

Discover how Auro GSH by Nayan Patel, PharmD, revolutionizes glutathione delivery in skin care, targeting oxidative stress for healthier skin.

Thazin Aung, PhD, discusses AI's role in standardizing immune cell evaluation in melanoma, enhancing diagnostic consistency and clinical decision-making.

Krystal Biotech enhances B-VEC's label, empowering DEB patients with at-home treatment options and improving quality of life through innovative gene therapy.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about the long-term safety of Amgen’s rocatinlimab for AD, the shared genetic backgrounds of cardiovascular diseases and psoriasis, the availability of LEO Pharma's delgocitinib cream, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Cigna’s removal of restrictions on home phototherapy, following a similar decision by Elevance Health, expands access to more than 66 million Americans.

Dermatologists and hairstylists unite to address scalp health, cultural practices, and patient care at the Science of Skin & Scalp Studio event.

Explore the complex genetic links between psoriasis and cardiovascular diseases, highlighting the IL-23 and IL-17 pathways' role in health risks.

Utilization management programs for atopic dermatitis may hinder patient care, causing treatment delays and increased costs despite advances in biologic therapies.

Darker skin tones face higher risks of photosensitivity and thermal burns during dual-wavelength laser therapy, highlighting the need for tailored treatment approaches.

New guidelines enhance understanding and treatment of genital psoriasis, addressing its psychological impact and improving patient-provider communication.

Discover how medium-to-deep chemical peels effectively treat refractory melasma, enhancing skin tone and quality with tailored approaches.

Upadacitinib maintained high EASI and itch response rates through nearly 3 years of treatment.